Trials / Recruiting
RecruitingNCT05789485
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
Dose-response of Aerobic Training During Chemotherapy for Gastrointestinal Cancers
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 216 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.
Detailed description
Study staff will also confirm remote training feasibility including items such as access to Wi-Fi and a treadmill for the study duration. During the feasibility assessment, if the participant is determined to not have access to Wi-Fi, we will offer a tablet with cellular capabilities. If patients do not have access to a treadmill, ExOnc staff may coordinate access to a fitness facility local to the participant, to facilitate treadmill access for the study duration. Fitness facility access will be provided through Wellhub, a service that allows use of nearby gyms and studios through a single app- based solution.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | structured treadmill walking | Three doses of AT (i.e., 90, 150, or 300 mins/week) will be tested. All doses will consist of individualized walking delivered up to 7 times per week delivered throughout treatment. |
Timeline
- Start date
- 2023-04-28
- Primary completion
- 2027-03-01
- Completion
- 2027-04-18
- First posted
- 2023-03-29
- Last updated
- 2026-04-16
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05789485. Inclusion in this directory is not an endorsement.